<DOC>
	<DOCNO>NCT02365623</DOCNO>
	<brief_summary>The purpose study explore safety efficacy TMC207 administer part multi-drug regimen 24 48-week treatment Japanese participant pulmonary multi-drug resistant tuberculosis ( MDR-TB ) , evaluate pharmacokinetics ( PK ) TMC207 primary metabolite M2 .</brief_summary>
	<brief_title>An Exploratory Study TMC207 Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis ( MDR-TB )</brief_title>
	<detailed_description>This open-label ( everyone know study intervention ) , single-arm , multicenter trial explore safety , efficacy PK TMC207 Japanese participant pulmonary MDR-TB . The participant receive TMC207 24 week combination individualize BR drug select Investigator Day -1 . Participants primarily assess sputum culture conversion Week 24 . Safety monitor throughout study .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Multidrug-Resistant</mesh_term>
	<mesh_term>Bedaquiline</mesh_term>
	<mesh_term>Diarylquinolines</mesh_term>
	<criteria>Must confirm pulmonary multidrug resistant tuberculosis ( MDRTB ) infection , define infection strain M. tuberculosis resistant rifampicin isoniazid ( RFP INH ) previous screen TB treatment Must confirm positive result acidfast bacillus ( AFB ) direct smear examination expectorate sputum specimen ( [ &gt; ] 1+ smearpositive ) Screening Phase sputum culture positive M. tuberculosis within precede 3 month A woman must childbearing potential : postmenopausal permanently sterilize otherwise incapable pregnancy , childbearing potential practicing highly effective method birth control consistent local regulation regard use birth control method man sexually active woman childbearing potential vasectomy must agree use barrier method birth control Must willing able adhere prohibition restriction specify protocol Must sign inform consent form ( ICF ) indicate understands purpose procedure require study willing participate study Has concomitant severe illness rapidly deteriorate health condition , include immune deficiency would make implementation protocol interpretation study result difficult otherwise make subject poor candidate clinical study Has complicate severe extrapulmonary manifestation TB , include central nervous system infection Participants significant cardiac arrhythmia require medication Participants abnormal electrocardiogram ( ECG ) parameter define protocol Has human immuno deficiency virus ( HIV ) antibody positive Screening Phase</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Pulmonary Multi-Drug Resistant Tuberculosis ( MDR-TB )</keyword>
	<keyword>TMC207</keyword>
	<keyword>Bedaquiline</keyword>
</DOC>